Connect with us
[bsa_pro_ad_space id=12]

Health

Military continues sex-misconduct fight with new guide for members, commanders

Published

OTTAWA — The Canadian Forces have a new manual on how to respond to sexual misconduct, aiming to close many of the gaps identified in the military’s policies on abuse in its ranks.

But some concerns remain unaddressed — including the “duty to report” regulation, which critics say discourages victims from seeking support if they aren’t ready or willing to begin a formal complaint.

The information in the 100-page document was previously spread in many places, which a Defence Department assessment published in February cited as a big reason many service members were confused and uncertain about the issue.

Some had only a vague understanding of what constituted inappropriate behaviour and what to do when an incident occurred, including how to support victims.

The new manual, which was developed in consultation with the military’s sexual-misconduct response centre (a counselling-oriented agency outside the chain of command) and a group of outside experts, goes to great pains to address the latter question in particular.

One of the first sections talks about how and why some people affected by sexual misconduct prefer to be called “victims,” others want to be referred to as “survivors,” and still others don’t like either identifier.

It also spells out the roles, responsibilities and training available for every service member as well as the additional responsibilities that commanding officers have in supporting victims and investigating incidents.

In a report last November, auditor general Michael Ferguson found many victims were not properly supported when they did speak up because of gaps in the services available and a lack of suitable training and policies.

To that end, commanders are also being given a new handout to help them wrap their heads around how sexual-misconduct cases are to be treated step by step — with a reminder at every step to check in with victims.

Those check-ins are not to be one-way updates, either, but opportunities to make sure each victim is getting the support needed and has input into how the case is handled.

The sexual-misconduct response centre is also working on plans to provide case workers, or victim-liaison officers, to service members affected by sexual misconduct.

But the “duty to report” regulation remains. It compels military members to report inappropriate or criminal behaviour, sexual or not, and begins a formal complaint process.

Defence chief Gen. Jonathan Vance has said the idea is to require anyone who learns of sexual misconduct to tell authorities so cases don’t get hidden, but the effect can be to drag them into the open against victims’ wishes. Ferguson and former Supreme Court justice Marie Deschamps, who conducted an explosive analysis of the extent of sexual misconduct in the Forces in 2015, have criticized the policy as actually discouraging victims from coming forward.

Vance has said the military is looking at ways to maintain the requirement while better protecting victims.

Ferguson also warned that military police often failed to provide information to victims about supports they can use or give them updates on cases, and there were concerns about a lack of training for chaplains and military health-care providers to help victims.

The federal victims’ ombudsman has also raised concerns about proposed legislation around victims’ rights in the military justice system, specifically that it does not require military police, prosecutors and others to inform victims that they have rights.

Lee Berthiaume, The Canadian Press

Community

Canada’s First Female Astronaut coming to Red Deer for Health Fundraiser

Published

on

From the Red Deer Regional Health Foundation

The world’s first neurologist in space is coming to Red Deer

The Red Deer Hospital fundraiser also features comedians from CBC Radio’s “The Debaters”

Red Deer Regional Health Foundation is pleased to announce a new event, The Lunch Box Experience, featuring three of Canada’s brightest stars, all coming together over lunch to raise funds for critical equipment for Red Deer Regional Hospital Centre.

Dr. Roberta Bondar, Canada’s first female astronaut and first neurologist in space, will be the keynote speaker on Monday, September 23, 2019 at Cambridge Red Deer Hotel & Conference Centre.  To motivate and inspire audiences, Dr. Bondar draws on her remarkable depth of expertise as an astronaut, physician, scientific researcher, author, and leader.

This is Dr. Bondar’s first visit to Central Alberta, and may be your only chance to experience this extraordinary woman in person.

 

Also performing are Erica Sigurdson and Dave Hemstad, comedians both regularly featured on CBC Radio’s smash hit The Debaters.  After lunch you’ll enjoy hysterical standup from both Erica and Dave, plus an episode of witty debater-style banter that will have you in stitches!

Tickets are $125 per person or table of 6 for $700; includes a unique lunch and are available now.

The Lunch Box Experience, formally part of the Red Deer Festival of Trees event line-up (Festival Business Lunch) is a fresh, new business networking opportunity.

Proceeds from this event will go towards ceiling-mounted patient lifts at Red Deer Regional Hospital Centre.

For more information, tickets, or sponsorship opportunities, please visit

The Lunch Box Experience:  A Red Deer Hospital Fundraiser

WHEN:     Monday, September 23, 2019

11:00am – 1:30pm

Cambridge Red Deer Hotel & Conference Centre

 

 

Continue Reading

Health

Health Canada announces changes aimed at dropping prices of patented drugs

Published

on

patented drugs

OTTAWA — The federal government is overhauling the way it regulates the cost of patented medicines, including ending comparisons to the United States — changes that Canada’s health minister is billing as the biggest step towards lower drug prices in a generation.

Health Canada’s long-awaited amendments to patented medicine regulations, unveiled Friday, include allowing the arm’s-length Patented Medicine Prices Review Board to consider whether the price of a drug reflects the value it has for patients. 

The list of countries that the quasi-judicial board uses to compare prices and gauge its own levels will no longer include the U.S. and Switzerland, both of which are home to some of the highest drug prices in the world.

That’s a category that has also long included Canada, something Health Minister Ginette Petitpas Taylor said she’s determined to change.

“If we look at their health care system, and we also look at the economies … it is really hard to compare their health care system to what we have here in Canada,” Petitpas Taylor said in an interview.

“When we changed the basket of countries, we changed them because we wanted to make sure could compare ourselves to similar jurisdictions that have similar health care systems and also similar populations.”

Jane Philpott, Petitpas Taylor’s predecessor in the portfolio, announced in May 2017 the government was embarking on a series of consultations on a suite of proposed regulatory changes related to the drug prices board.

Philpott said the prices review board — first created 30 years ago to ensure companies do not use monopolies to charge excessive costs — was limited in its ability to protect consumers from high drug prices.  The government expressed at the time it hoped to have the new regulations in place no later than the end of 2018.

It has taken a long time for the final changes to be put in place, Petitpas Taylor acknowledged, but she said that’s only because the government wanted to ensure it consulted with all industry stakeholders, patient groups, and people who worked in the field.

Former Bank of Canada governor David Dodge was brought on as a third-party reviewer to conduct a cost-benefit analysis, said Petitpas Taylor, who anticipates the amendments announced Friday will save Canadians approximately $13 billion over 10 years on patented drug costs.

“We took our time, we did our due diligence,” she said. “At the end of the day, as Canada’s health minister, my number 1 priority is making sure that medication is available for all Canadians and when we say that Canada’s among the top three countries that pay the highest drug prices in the world, that’s just not acceptable.”

The review board now has the tools and information it needs to meaningfully protect Canadian consumers from excessive prices, board chair Dr. Mitchell Levine said in a statement.

The board hopes to have constructive talks with partners and stakeholders in coming months to make the necessary changes to its guidelines and put the regulatory amendments into effect, he added.

Petitpas Taylor called the changes a “huge step” towards a national pharmacare plan — the public, single-payer system of drug coverage Prime Minister Justin Trudeau has promised to pursue.

NDP Leader Jagmeet Singh, whose party appears poised to make its own proposal for a national plan a central component of its election campaign, dismissed Friday’s announcement as little more than a stall tactic.

“The best way Canada can lower the price of drugs is well documented: buying them in bulk using the negotiating power of a 37-million-person single-payer pharmacare plan,” Singh said in a statement.

“But big pharmaceutical and insurance companies don’t want that, so after meeting with them more than 700 times since 2015, Trudeau’s Liberals are stalling pharmacare, and therefore making life easier for big pharma.”

Innovative Medicines Canada, which represents the pharmaceutical industry, warned in a statement that the regulatory amendments would limit the access of Canadian patients to new, cutting-edge treatments, and would also discourage investment in Canada’s life science sector.

“Our fear is that patients will be worse off,” said IMC president Pamela Fralick.

John Adams, the volunteer chairman of the Best Medicines Coalition, a non-profit organization representing 28 national patient organizations, said Friday that he shares the concerns that patients will be adversely affected.

“If one drug developer decides not to come to Canada or to withdraw from Canada, Canadian patients will suffer and possibly die prematurely,” he said in an interview.

Adams accused Ottawa of ignoring input from patient groups, and said one of the key issues is that the government hasn’t examined drug access in the countries in the new basket over the past 15 years compared to Canada.

The list now includes Germany, Japan, Sweden, the U.K., Italy, Belgium, Spain, the Netherlands, Australia, France and Norway. The former list included the U.S., Switzerland, Germany, Sweden, the U.K., Italy and France.

—Follow @kkirkup on Twitter

Kristy Kirkup, The Canadian Press


Continue Reading

august, 2019

tue06augAll Daysun29sepHot Mess - Erin Boake featured at Red Deer Museum and Art Gallery(All Day)

sat24augAll Daysun25Fort Normandeau Days(All Day) Fort Normandeau, 28054 Range Road 382

sat24aug10:00 am12:00 pmRed Deer River Naturalists Bird Focus Group Walk10:00 am - 12:00 pm MST Three Mile Bend Recreation Area

Trending

X